2024-03-12 20:45:07 ET
Moderna, Inc. (MRNA)
Barclays 26th Annual Global Healthcare Conference Call
March 12, 2024 14:35 ET
Company Participants
Lavina Talukdar - Senior Vice President and Head, Investor Relations
Conference Call Participants
Gena Wang - Barclays
Presentation
Gena Wang
Welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover SMID cap biotech. It is my great pleasure to introduce our next presenting company, Moderna. With us today, we have Lavina Talukdar, SVP, Head of Investor Relations.
Question-and-Answer Session
Q - Gena Wang
So Lavina, I think we don’t need to have an overview. Everyone knows Moderna’s very well. I will start with COVID revenue regarding 2024 guidance. You do give a guidance of $4 billion total revenue. And within that, you have say $1 billion is from COVID APA and the $2 plus billion in U.S. revenue and an additional $1 billion is ex-U.S. COVID-plus – sorry, the RSV and the international COVID, right? So maybe starting with APA, how confident we are with this $1 billion that will be executed in 2024?...
Read the full article on Seeking Alpha
For further details see:
Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript)